Organon (OGN) Q2 2026 earnings summary

Executive summary

• Entered definitive agreement for acquisition by Sun Pharma at $14.00 per share, with stockholder approval received and closing expected in early 2027.

• Divested Jada System for up to $465 million, recognizing an $81 million net gain.

• Amended and expanded biosimilar collaborations with Samsung Bioepis, including new commercialization rights and extended terms.

Financial highlights

• Q2 2026 revenue was $1.56 billion, down 2% year-over-year; six-month revenue was $3.02 billion, down 3%.

• Q2 2026 net income was $108 million, down from $145 million in Q2 2025; six-month net income was $254 million, up from $232 million.

• Gross profit for Q2 2026 was $847 million, down 3% year-over-year; six-month gross profit was $1.63 billion, down 5%.

• Diluted EPS for Q2 2026 was $0.40, compared to $0.56 in Q2 2025.

• Cash and cash equivalents at June 30, 2026 were $1.13 billion.

Outlook and guidance

• Expect continued negative impact from volume-based procurement in China and loss of exclusivity for certain products.

• Anticipate stabilization in Nexplanon sales as expanded use from new label offsets reinsertion headwinds in H2 2026.

• Ongoing adaptation of business and sales strategies to address changing market and regulatory conditions.